Why Did Ken Griffin Buy Sweetgreen Stock?
In Q1, Ken Griffin’s Citadel Advisors purchased nearly 1.3 million…
Buy
53
HCM Quote, Financials, Valuation and Earnings
Last price:
$17.76
Seasonality move
:
12.21%
Day range:
$17.01 - $17.30
52-week range:
$11.51 - $21.50
Dividend yield:
0%
P/E ratio:
85.75x
P/S ratio:
4.75x
P/B ratio:
3.86x
Volume:
110K
Avg. volume:
78.4K
1-year change:
-4.24%
Market cap:
$2.9B
Revenue:
$630.2M
EPS (TTM):
$0.20
Analysts' Opinion
-
Consensus RatingHUTCHMED (China) has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $25.67, HUTCHMED (China) has an estimated upside of 49.67% from its current price of $17.15.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $14.70 representing 100% downside risk from its current price of $17.15.
Fair Value
-
According to the consensus of 12 analysts, HUTCHMED (China) has 49.67% upside to fair value with a price target of $25.67 per share.
HCM vs. S&P 500
-
Over the past 5 trading days, HUTCHMED (China) has overperformed the S&P 500 by 11.68% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
HUTCHMED (China) does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
HUTCHMED (China) has grown year-over-year revenues for 3 quarters straight. In the most recent quarter HUTCHMED (China) reported revenues of --.
Earnings Growth
-
HUTCHMED (China) has grown year-over-year earnings for 0 quarters straight. In the most recent quarter HUTCHMED (China) reported earnings per share of --.
Enterprise value:
2.2B
EV / Invested capital:
--
Price / LTM sales:
4.75x
EV / EBIT:
1,241.29x
EV / Revenue:
3.48x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-125.65x
Price / Operating cash flow:
17.47x
Enterprise value / EBITDA:
155.31x
Gross Profit (TTM):
$281.3M
Return On Assets:
2.97%
Net Income Margin (TTM):
5.99%
Return On Equity:
4.99%
Return On Invested Capital:
4.51%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2020-06-30 | 2021-06-30 | |
| Income Statement | ||||||
| Revenue | $204.4M | $209M | $264.1M | $55.2M | $75.8M | |
| Gross Profit | -- | -- | -- | $12.9M | $17.5M | |
| Operating Income | -- | -- | -- | -$45.7M | -$80.5M | |
| EBITDA | -- | -- | -- | -$45.7M | -$80.5M | |
| Diluted EPS | -- | -- | -- | -$0.25 | -$0.40 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $839.9M | $1.1B | $1.1B | |
| Total Assets | -- | -- | $1B | $1.3B | $1.3B | |
| Current Liabilities | -- | -- | $353.9M | $403M | $376.6M | |
| Total Liabilities | -- | -- | $392.6M | $536.4M | $502.3M | |
| Total Equity | -- | -- | $636.9M | $743.4M | $771.9M | |
| Total Debt | -- | -- | $18.1M | $79.3M | $82.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2020-06-30 | 2021-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$48.6M | -$58.4M | -$99.7M | -$26.6M | -$49M | |
| Cash From Investing | -- | -- | -- | -$41.3M | -$315.9M | |
| Cash From Financing | -- | -- | -- | -$14.4M | $605.1M | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
HCM
Sector
Market Cap
$2.9B
$33.4M
Price % of 52-Week High
79.77%
47.1%
Dividend Yield
0%
0%
Shareholder Yield
0.86%
-0.6%
1-Year Price Total Return
-4.24%
-36.6%
Beta (5-Year)
0.516
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$15.52
200-day SMA
Buy
Level
$16.00
Bollinger Bands (100)
Buy
Level
13.36 - 15.68
Chaikin Money Flow
Buy
Level
21.6M
20-day SMA
Buy
Level
$14.25
Relative Strength Index (RSI14)
Buy
Level
75.10
ADX Line
Buy
Level
22.2
Williams %R
Sell
Level
-3.5714
50-day SMA
Buy
Level
$14.33
MACD (12, 26)
Buy
Level
0.59
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
15.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.1763)
Buy
CA Score
(Annual)
Level (0.1183)
Sell
Beneish M-Score
(Annual)
Level (-1.6283)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.061)
Buy
Piotroski F Score
(Annual)
Level (4)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Stock Forecast FAQ
In the current month, HCM has received 9 Buy ratings 3 Hold ratings, and 0 Sell ratings. The HCM average analyst price target in the past 3 months is $25.67.
-
Where Will HUTCHMED (China) Stock Be In 1 Year?
According to analysts, the consensus estimate is that HUTCHMED (China) share price will rise to $25.67 per share over the next 12 months.
-
What Do Analysts Say About HUTCHMED (China)?
Analysts are divided on their view about HUTCHMED (China) share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that HUTCHMED (China) is a Sell and believe this share price will drop from its current level to $14.70.
-
What Is HUTCHMED (China)'s Price Target?
The price target for HUTCHMED (China) over the next 1-year time period is forecast to be $25.67 according to 12 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is HCM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for HUTCHMED (China) is a Buy. 9 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of HCM?
You can purchase shares of HUTCHMED (China) via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase HUTCHMED (China) shares.
-
What Is The HUTCHMED (China) Share Price Today?
HUTCHMED (China) was last trading at $17.76 per share. This represents the most recent stock quote for HUTCHMED (China). Yesterday, HUTCHMED (China) closed at $17.15 per share.
-
How To Buy HUTCHMED (China) Stock Online?
In order to purchase HUTCHMED (China) stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Planet Labs’ Stock Go Next?
On 4 June 2025 Planet reported Q1 FY 2026 revenue of $66.3 million, up 10% year over…
Where Will VICI Properties Be in 5 Years?
VICI Properties (NYSE:VICI) is a real estate investment trust focused…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
73
OKLO alert for Jun 12
Oklo [OKLO] is down 1.96% over the past day.
Buy
87
SMR alert for Jun 12
NuScale Power [SMR] is down 1.25% over the past day.
Buy
53
PLAY alert for Jun 12
Dave & Buster's Entertainment [PLAY] is up 0.98% over the past day.
